|
|
|
|
|
|
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
一项评价Uproleselan联合化疗对比单纯化疗治疗中国复发或难治性急性髓系白血病受试者有效性的随机、双盲、对照的III期桥接临床研究
本研究的主要目的是比较接受Uproleselan联合化疗与单纯化疗的受试者的总生存期(OS)。
A Phase 3 Randomized, Double-Blinded Bridging Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Chinese Patients With Relapsed/Refractory Acute Myeloid Leukemia
This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML
Phase I Study on Safety, Tolerance, and Pharmacokinetics of APL-102 Capsule in Patients With Advanced Solid Tumors
This study will evaluate the safety and tolerability of APL-102 Capsule and characterize the pharmacokinetic (PK) profile in advanced solid tumor patients.
100 项与 浙江冠科美博生物科技有限公司 相关的临床结果
0 项与 浙江冠科美博生物科技有限公司 相关的专利(医药)
100 项与 浙江冠科美博生物科技有限公司 相关的药物交易
100 项与 浙江冠科美博生物科技有限公司 相关的转化医学